<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04050826</url>
  </required_header>
  <id_info>
    <org_study_id>FDA02_AIM2_Main</org_study_id>
    <nct_id>NCT04050826</nct_id>
  </id_info>
  <brief_title>An Exploratory Study in Healthy Volunteers to Identify Factors Influencing Bioequivalence Studies on Moderately Lipophilic Drugs Using Dermal Open Flow Microperfusion (dOFM)</brief_title>
  <official_title>An Exploratory Study in Healthy Volunteers to Identify Factors Influencing Bioequivalence Studies on Moderately Lipophilic Drugs Using Dermal Open Flow Microperfusion (dOFM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joanneum Research Forschungsgesellschaft mbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Joanneum Research Forschungsgesellschaft mbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this clinical study is to develop a general bioequivalence (BE) testing
      method using dermal open flow microperfusion (dOFM) for dermatological drug products. In this
      study BE of different lidocaine/prilocaine products will be assessed and factors that
      influence dOFM data variability will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will involve 20 healthy adult participants. Dermal pharmacokinetic (PK) profile of
      three different lidocaine/prilocaine products will be assessed in parallel at different skin
      sites on the same participant.

      For BE evaluations a reference product will be compared against itself and an approved
      generic test product as positive control and against a non-equivalent test product as
      negative control. Additionally different non-invasive measurements (e.g. TEWL) will be
      conducted and results will be correlated with lidocaine/prilocaine PK data to identify
      factors that might influence skin penetration.

      dOFM probes will be inserted into the dermis to monitor the dermal drug concentrations up to
      12 h post-dose in topically treated skin sites. Blood samples will be drawn to rule out
      systemic appearance of lidocaine and/or prilocaine.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the dermal concentration versus time curve for lidocaine</measure>
    <time_frame>13 hours</time_frame>
    <description>Dermal concentrations (ng/mL) of lidocaine will be measured to calculate the area under the dermal concentration versus time curve AUC (ng*h/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the dermal concentration versus time curve for prilocaine</measure>
    <time_frame>13 hours</time_frame>
    <description>Dermal concentrations (ng/mL) of prilocaine will be measured to calculate the area under the dermal concentration versus time curve AUC (ng*h/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal dermal concentration of lidocaine</measure>
    <time_frame>13 hours</time_frame>
    <description>Dermal concentrations (ng/mL) of lidocaine will be measured to calculate the maximal dermal concentration (ng/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal dermal concentration of prilocaine</measure>
    <time_frame>13 hours</time_frame>
    <description>Dermal concentrations (ng/mL) of prilocaine will be measured to calculate the maximal dermal concentration (ng/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood lidocaine concentrations versus time curve</measure>
    <time_frame>13 hours</time_frame>
    <description>Lidocaine concentrations (ng/mL) in the blood will be measured to obtain the concentration-time curves in the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood prilocaine concentrations versus time curve</measure>
    <time_frame>13 hours</time_frame>
    <description>Prilocaine concentrations (ng/mL) in the blood will be measured to obtain the concentration-time curves in the blood.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <condition>Dermal Pharmacokinetic Measurements</condition>
  <arm_group>
    <arm_group_label>Dermal Pharmacokinetic study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dOFM after topical application of three lidocaine/prilocaine products in 20 participants.
After baseline sampling (1 hour pre-dose) the three lidocaine/prilocaine products will be applied and removed after 3 hours. ISF and blood sampling will be continued for a duration of 12 hours post-dose. Additionally different physical parameters (e.g. TEWL) will be measured.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine 2.5% and Prilocaine 2.5% cream, USP (Actavis Pharma incorporated, USA)</intervention_name>
    <description>Topical application</description>
    <arm_group_label>Dermal Pharmacokinetic study</arm_group_label>
    <other_name>Reference product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine 2.5% and Prilocaine 2.5% cream (E. Fougera &amp; Co. a division of Fougera Pharmaceuticals Inc., USA)</intervention_name>
    <description>Topical application</description>
    <arm_group_label>Dermal Pharmacokinetic study</arm_group_label>
    <other_name>Generic test product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oraqix Parodontal-Gel (Dentsply Detrey GmbH, Germany)</intervention_name>
    <description>Topical application</description>
    <arm_group_label>Dermal Pharmacokinetic study</arm_group_label>
    <other_name>Non-equivalent test product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dermal open flow microperfusion</intervention_name>
    <description>Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.
16 dOFM probes will be implanted per participant (8 test-sites; 2 dOFM probes per test-site).
From each dOFM probe 13 samples will be taken (1 pre-dose, 12 post-dose).</description>
    <arm_group_label>Dermal Pharmacokinetic study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>1 sample will be taken pre-dose and 12 samples post-dose.</description>
    <arm_group_label>Dermal Pharmacokinetic study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 to 65 years inclusive.

          2. Males and/or non-pregnant, non-breast feeding females (subjects need to be informed
             about adequate contraceptive methods).

          3. Able to read, understand, and sign the written informed consent form.

          4. Willing to follow the protocol requirements and comply with protocol restrictions.

        Exclusion Criteria:

          1. Social Habits

               1. Smoker who is not willing to restrain from smoking during the in-house visit
                  (Visit 2).

               2. History of drug and/or alcohol abuse within one year of start of study as judged
                  by the investigator.

          2. Medications: Current treatment with systemically effective corticosteroids, monoamine
             oxidase (MAO) inhibitors, systemic non-selective beta-blockers, warfarin or
             anticholinergic drugs, or use of any medications referred in the prescription
             information of the products. Hormonal contraceptive or hormone replacement therapy,
             routine vitamins or other prescribed medication are allowed if dose is stable.

          3. Diseases

               1. Congenital or idiopathic methemoglobinemia

               2. History of deep vein thrombosis (DVT)/pulmonary emboly (PE)

               3. Inherited blood disorders (such as factor V Leiden) who are prone to
                  hypercoagulable state

               4. Glucose-6-phosphate dehydrogenase deficiencies

               5. Presence of any acute or chronic diseases or malignancies unless deemed not
                  clinically significant by the investigator.

          4. Any reason which, in the opinion of the investigator, would prevent the subject from
             safely participating in the study.

          5. Any abnormalities found at physical examination or vital signs, unless deemed not
             clinically significant by the investigator.

          6. Clinically significant abnormal laboratory evaluation results, as deemed by the
             investigator.

          7. Clinically significant abnormal 12-lead ECG at screening, as deemed by the
             investigator.

          8. Positive results to the test for hepatitis B antigen or hepatitis C antibodies.

          9. Positive HIV test.

         10. Positive alcohol breath test.

         11. Blood donation within 30 days or significant loss of blood or plasma (more than 550
             ml) within 90 days prior to screening.

         12. Subjects who have received an investigational drug within 30 days prior to the initial
             dose of study medication.

         13. Any food allergy, intolerance, restriction or special diet that, in the opinion of the
             investigator, could contraindicate the subject's participation in this study.

         14. Known or suspected allergy/hypersensitivity to lidocaine or prilocaine, known history
             of sensitivity to local anesthetics of the amide type or to any other component of the
             product, other related products, or any inactive ingredients.

         15. Tattoos or broken and/or damaged skin at the application areas.

         16. Active skin diseases like psoriasis or atopic dermatitis, as judged by the
             investigator.

         17. Scarring at the anterior part of the thighs.

         18. Subjects prone to keloid or hypertrophic scar formation or any known wound healing
             disorder.

         19. Recent and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of
             fainting, palpitations, etc.), as judged by the investigator.

         20. Not willing to avoid excessive sun exposure, steam baths, sauna, swimming and other
             strenuous activities between Visit 2 and the end-of-study examination to ensure good
             tissue regeneration.

         21. Not willing to refrain from shaving the anterior of the thighs or using skin care
             products on the anterior of the thighs for at least 5 days prior to start of Visit 2.

         22. Pronounced hairiness on the thighs that may negatively affect BE testing.

         23. Known allergy/hypersensitivity to any of the materials/supplies used during the study.

         24. Presence of needle phobia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Pieber, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Franz Feichtner, PhD</last_name>
    <phone>+43316876</phone>
    <phone_ext>4003</phone_ext>
    <email>franz.feichtner@joanneum.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katrin Tiffner</last_name>
    <phone>+43316876</phone>
    <phone_ext>4121</phone_ext>
    <email>katrin.tiffner@joanneum.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CTU - Clinical Trials Unit, Medical University Graz</name>
      <address>
        <city>Graz</city>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas Pircher</last_name>
      <phone>+43316385</phone>
      <phone_ext>72834</phone_ext>
      <email>thomas.pircher@medunigraz.at</email>
    </contact>
    <contact_backup>
      <last_name>Eva Svehlikova, PhD</last_name>
      <phone>+43316385</phone>
      <phone_ext>72835</phone_ext>
      <email>eva.svehlikova@medunigraz.at</email>
    </contact_backup>
    <investigator>
      <last_name>Eva Svehlikova, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rasa Vitonyte, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ines Mursic, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Pieber, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>https://www.fda.gov/downloads/Drugs/NewsEvents/UCM591892.pdf</url>
    <description>In Vivo Dermal Open Flow Microperfusion: A Novel Approach to Evaluating Topical Bioavailability and Bioequivalence</description>
  </link>
  <reference>
    <citation>Bodenlenz M, Tiffner KI, Raml R, Augustin T, Dragatin C, Birngruber T, Schimek D, Schwagerle G, Pieber TR, Raney SG, Kanfer I, Sinner F. Open Flow Microperfusion as a Dermal Pharmacokinetic Approach to Evaluate Topical Bioequivalence. Clin Pharmacokinet. 2017 Jan;56(1):91-98. doi: 10.1007/s40262-016-0442-z. Erratum in: Clin Pharmacokinet. 2017 Jan;56(1):99.</citation>
    <PMID>27539717</PMID>
  </reference>
  <reference>
    <citation>Bodenlenz M, Dragatin C, Liebenberger L, Tschapeller B, Boulgaropoulos B, Augustin T, Raml R, Gatschelhofer C, Wagner N, Benkali K, Rony F, Pieber T, Sinner F. Kinetics of Clobetasol-17-Propionate in Psoriatic Lesional and Non-Lesional Skin Assessed by Dermal Open Flow Microperfusion with Time and Space Resolution. Pharm Res. 2016 Sep;33(9):2229-38. doi: 10.1007/s11095-016-1960-y. Epub 2016 Jun 6.</citation>
    <PMID>27271272</PMID>
  </reference>
  <reference>
    <citation>Bodenlenz M, Aigner B, Dragatin C, Liebenberger L, Zahiragic S, Höfferer C, Birngruber T, Priedl J, Feichtner F, Schaupp L, Korsatko S, Ratzer M, Magnes C, Pieber TR, Sinner F. Clinical applicability of dOFM devices for dermal sampling. Skin Res Technol. 2013 Nov;19(4):474-83. doi: 10.1111/srt.12071. Epub 2013 Apr 13.</citation>
    <PMID>23581539</PMID>
  </reference>
  <reference>
    <citation>Dragatin C, Polus F, Bodenlenz M, Calonder C, Aigner B, Tiffner KI, Mader JK, Ratzer M, Woessner R, Pieber TR, Cheng Y, Loesche C, Sinner F, Bruin G. Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion. Exp Dermatol. 2016 Feb;25(2):157-9. doi: 10.1111/exd.12863. Epub 2015 Nov 23.</citation>
    <PMID>26439798</PMID>
  </reference>
  <reference>
    <citation>Tiffner K, Boulgaropoulos B, Höfferer C, Birngruber T, Porksen N, Linnebjerg H, Garhyan P, Lam ECQ, Knadler MP, Pieber TR, Sinner F. Quantification of Basal Insulin Peglispro and Human Insulin in Adipose Tissue Interstitial Fluid by Open-Flow Microperfusion. Diabetes Technol Ther. 2017 May;19(5):305-314. doi: 10.1089/dia.2016.0384. Epub 2017 Mar 22.</citation>
    <PMID>28328234</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dermal open flow microperfusion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Prilocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

